A Registry for People With Lung Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying people with early-stage lung cancer (specifically, tumors that are small and located on the outer part of the lung) to learn more about their experiences and outcomes after surgery. The trial is currently recruiting participants who are at least 18 years old and have a specific type of lung cancer called non-small cell lung cancer (NSCLC). To be eligible, participants must be planning to have a type of surgery called segmentectomy, which involves removing a small part of the lung that contains the tumor.

If you decide to participate, you will be asked to fill out questionnaires at three different times: before your surgery, a few weeks after your surgery, and again six months later. This information will help researchers understand how patients feel and how their health changes after treatment. It's important to know that this study is being carefully monitored by a team of experts, and it aims to improve care for future lung cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Clinical stage I tumor (AJCC 8th edition) suitable for segmentectomy, according to the treating thoracic surgeon
• • o Note: Patients must undergo segmentectomy for a peripheral lesion ≤2 cm to be included in the primary analysis. Individual ligation of the segmental artery(s) and segmental bronchus is the minimum definition for a segmentectomy. Division of the segmental vein and intraoperative frozen section to assess surgical margins and N1 lymph nodes are strongly encouraged, but the absence of either is not a criterion for exclusion.
• • Pathology of NSCLC o Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology.
• Other considerations:
• • Patients with ground-glass opacities will have their tumor size recorded on the basis of the size of the solid component.
• • Any non-lung cancer treated in the past with no obvious recurrence or ongoing treatment is not a criterion for exclusion.
• • The registry study will be monitored by Thoracic Surgery team at MSK.
• • This study will be in collaboration with the Thoracic Surgical Oncology Group (TSOG) of the American Association for Thoracic Surgery.
• Exclusion Criteria:
• • Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
• • History of chemotherapy or radiation therapy for a previous lung cancer
• • Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
• • Carcinoid tumors
• • History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
• • Actively receiving treatment for other malignancies
• • Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.
• • Multi-segmental resection from the same lobe is not a criterion for exclusion.